Literature DB >> 24551305

Smoothelin and caldesmon are reliable markers for distinguishing muscularis propria from desmoplasia: a critical distinction for accurate staging colorectal adenocarcinoma.

Jordan A Roberts1, Lindsay Waters1, Jae Y Ro1, Qihui Jim Zhai2.   

Abstract

An accurate distinction between deep muscularis propria invasion versus subserosal invasion by colonic adenocarcinoma is essential for the accurate staging of cancer and subsequent optimal patient management. However, problems may arise in pathologic staging when extensive desmoplasia blurs the junction between deep muscularis propria and subserosal fibroadipose tissue. To address this issue, forty-three (43) cases of colonic adenocarcinoma resections from 2007-2009 at The Methodist Hospital in Houston, TX were reviewed. These cases were selected to address possible challenges in differentiating deep muscularis propria invasion from superficial subserosal invasion based on H&E staining alone. Immunohistochemical staining using smooth muscle actin (SMA), smoothelin, and caldesmon were performed on 51 cases: 8 cases of pT1 tumors (used mainly as control); 12 pT2 tumors; and 31 pT3 tumors. All 51 (100%) had diffuse, strong (3+) immunoreactivity for caldesmon and smoothelin in the muscularis propria with a granular cytoplasmic staining pattern. However, the desmoplastic areas of these tumors, composed of spindled fibroblasts and myofibroblasts, showed negative immunostaining for caldesmon and smoothelin (0/35). SMA strongly stained the muscularis propria and weakly (1+) or moderately (2+) stained the spindled fibroblasts in the desmoplastic areas (the latter presumably because of myofibroblastic differentiation). Compared to SMA, caldesmon and smoothelin are more specific stains that allow better delineation of the muscularis propria from the desmoplastic stromal reaction which provides a critical aide for proper staging of colonic adenocarcinoma and subsequent patient care.

Entities:  

Keywords:  Colon adenocarcinoma; cancer staging; immunohistochemistry

Mesh:

Substances:

Year:  2014        PMID: 24551305      PMCID: PMC3925929     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  14 in total

1.  A novel isoform of the smooth muscle cell differentiation marker smoothelin.

Authors:  J Krämer; A M Aguirre-Arteta; C Thiel; C M Gross; R Dietz; M C Cardoso; H Leonhardt
Journal:  J Mol Med (Berl)       Date:  1999-02       Impact factor: 4.599

2.  Characterisation of myofibroblasts in fibrovascular tissues of primary and recurrent pterygia.

Authors:  A Touhami; M A Di Pascuale; T Kawatika; M Del Valle; R H Rosa; S Dubovy; S C G Tseng
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

3.  [The prognostic role of anatomo-pathological factors in colorectal cancer: an univariate analysis].

Authors:  C Coco; P Magistrelli; F M Vecchio; G Roncolini; P Granone; D D'Ugo; A Picciocchi
Journal:  Ann Ital Chir       Date:  1991 Jul-Aug       Impact factor: 0.766

4.  Prognostic and survival analysis of 837 Chinese colorectal cancer patients.

Authors:  Ying Yuan; Mo-Dan Li; Han-Guang Hu; Cai-Xia Dong; Jia-Qi Chen; Xiao-Fen Li; Jing-Jing Li; Hong Shen
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

5.  Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma.

Authors:  Hiroshi Miyamoto; Rajni B Sharma; Peter B Illei; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

6.  Smoothelin is a specific and robust marker for distinction of muscularis propria and muscularis mucosae in the gastrointestinal tract.

Authors:  Matteo Montani; Thore Thiesler; Glen Kristiansen
Journal:  Histopathology       Date:  2010-08       Impact factor: 5.087

7.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.

Authors:  Xiaofei Qiu; Elizabeth Montgomery; Baocun Sun
Journal:  Hum Pathol       Date:  2008-04-08       Impact factor: 3.466

9.  Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma.

Authors:  Gladell P Paner; Steven S Shen; Shawn Lapetino; Girish Venkataraman; Güliz A Barkan; Marcus L Quek; Jae Y Ro; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2009-01       Impact factor: 6.394

10.  Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells.

Authors:  F T van der Loop; G Schaart; E D Timmer; F C Ramaekers; G J van Eys
Journal:  J Cell Biol       Date:  1996-07       Impact factor: 10.539

View more
  1 in total

Review 1.  Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.

Authors:  Alicia M Hidalgo-Estévez; Konstantinos Stamatakis; Marta Jiménez-Martínez; Ricardo López-Pérez; Manuel Fresno
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.